Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Cancer Res. 2013 Jun 6;73(15):4697–4710. doi: 10.1158/0008-5472.CAN-13-0930

Figure 5. Activation of Kras concomitant with PTEN loss (PTENKO/Kras) caused progesterone resistance.

Figure 5

(A) Schema for generation and hormonal therapy of PTENKO/Kras tumors (B) Despite co-administration of estrogen and progesterone PTENKO/Kras tumors did not resolve (n=8) (a&b) and were similar to placebo treated counterparts (n=8) (c&d). (C) No obvious differences in histology was detected with progesterone treatment (a vs. b). PTEN was absent in tumor epithelia (c&d). The hormone receptor expression was similar between progesterone and placebo treated tumors (e&g vs. f&h). (D) A high proliferation index was detected in tumors despite hormonal therapy (a vs. b). Scale bars are equal to 2 mm in B, and 100 μm in C&D.